• Home
  • [draft]About OVAWatch

[draft]About OVAWatch

OVA1 Protein Biomarker Testing helps detect ovarian cancer sooner

OVA1®, the first-generation Multivariate Index Assay (MIA), minimizes the uncertainty of the pre-surgical adnexal mass work-up.

Using five biomarkers and the patient’s menopausal status, the FDA-cleared OVA1 test helps detect more ovarian cancer than standard testing. This can initiate optimal surgery with a cancer specialist earlier in the care pathway.

Practice Bulletin 174: American Congress of Obstetricians and Gynecologists ACOG Practice Bulletin on “Evaluation and Management of Adnexal Masses”

Read statement here

Level B guidelines state that the physician may use risk assessment tools such as OVA1 (“Multivariate Index Assay”) as listed in the bulletin. The new guidelines suggest that if an elevated risk of malignancy does exist, then the provider must consult with or refer to a gynecologic oncologist.

– American Congress of Obstetricians and Gynecologists

Recent data have suggested that such tests, along with physician clinical assessment, may improve detection rates of malignancies among women with pelvic masses planning surgery.

– Society of Gynecologic Oncology
Society of Gynecologic Oncology Position Statement on “Multiplex Serum Testing for Women with Pelvic Mass”

Read statement here